Toll-like receptor 7 a novel non-invasive inflammatory genetic sensor for ulcerative colitis remission monitoring

Asadzadeh-Aghdaei, Hamid; Rejali, Leili; Nourian, Mahyar; Chaleshi, Vahid; Zamani, Naghmeh; Baradaran-Ghavami, Shaghayegh; Nemati, Mohsen; Shahrokh, Shabnam; Norouzinia, Mohsen; Vosough, Massoud; Nazemalhosseini-Mojarad, Ehsan; Zali, Mohammadreza

Toll-like receptor 7 a novel non-invasive inflammatory genetic sensor for ulcerative colitis remission monitoring

Authors

¹ Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Mahak Hematology Oncology Research Center (Mahak-HORC), Mahak Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴ Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

Abstract

Background: Ulcerative colitis (UC) and Crohn's disease (CD) are two major types of inflammatory bowel diseases (IBDs). Toll-like receptors (TLRs) are expressed in the innate immune system compartments, in charge of identifying a wide range of microorganisms. The aim of the present study was to evaluate the expression of TLR-2, -7, and -8 in peripheral blood mononuclear cells (PBMC) of UC patients as a novel non-invasive primary inflammation sensor for monitoring the clinical course of UC candidates.
Materials and Methods: In this cross-sectional study, total RNA was extracted from the PBMC of 42 UC patients along with 20 healthy donors. The mRNA levels of TLR-2, -7, and -8 were assessed using the quantitative real-time polymerase chain (qRT-PCR) reaction.
Results: The present research study demonstrated no significant changes in TLR-2 mRNA expression in UC patients in comparison with the control group (P = 0.1264), whereas significant elevation (P = 0.0008) was distinguished in the TLR-7 expression of UC participants specifically during the remission course compared with healthy donors and flareup patients (P = 0.0004 and P = 0.0063, respectively). The last selected TLR, TLR-8 was not shown remarkable changes either between UC patients and the control group or between clinical courses of the disease.
Conclusion: Here, among three nominated TLRs for predicting UC patients, TLR-7 was potentially selected according to the significant difference in mRNA expression in flareup UC patients and control donors. TLR-7 could be used as a novel non-invasive biomarker for monitoring UC patients in the active course of the disease.

Keywords

References

1.	Uhlig HH. Monogenic diseases associated with intestinal inflammation: Implications for the understanding of inflammatory bowel disease. Gut 2013;62:1795-805.
2.	Macer BJ, Prady SL, Mikocka-Walus A. Antidepressants in inflammatory bowel disease: A systematic review. Inflamm Bowel Dis 2017;23:534-50.
3.	Zaeem Sibtain D, Uppal ST, Sumalani KK, Qaiser MA, Mahmood Q, Butt N. Inflammatory bowel disease in developing world: Prevalence, clinical presentations, diagnostic and therapeutic challenges. Ann Roman Soc Cell Biol 2021;25:1092-102.
4.	Chaleshi V, Safari MT, Tarban P, Nourian M, Balaii H, Shahrokh S, et al. Evaluation of IL-17B and IL-17F mRNA expression in peripheral blood mononuclear cells and association with clinical outcome of IBD Patients. Gastroenterol Hepatol Bed Bench 2017;10:S79-80.
5.	Kaplan GG. The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015;12:720-7.
6.	Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep 2019;21:1-9.
7.	Cosnes J, Gower–Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.e4.
8.	Olfatifar M, Zali MR, Pourhoseingholi MA, Balaii H, Ghavami SB, Ivanchuk M, et al. The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study. BMC Gastroenterol 2021;21:1-8.
9.	Geboes K. Histopathology of Crohn's disease and ulcerative colitis. InflammBowel Dis 2003;4:210-28.
10.	DeRoche TC, Xiao S-Y, Liu X. Histological evaluation in ulcerative colitis. Gastroenterol Rep 2014;2:178-92.
11.	Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: Mucosal immune cells in intestinal inflammation. Gut 2013;62:1653-64.
12.	Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 2015;160:447-60.
13.	Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 2012;1:15-21.
14.	Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, et al. Evaluation of tumor necrosis factor (TNF)-α mRNA expression level and the rs1799964 polymorphism of the TNF-α gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomed Rep 2017;6:698-702.
15.	Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature 2020;578:527-39.
16.	Hyams JS, Thomas SD, Gotman N, Haberman Y, Karns R, Schirmer M, et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): A multicentre inception cohort study. Lancet 2019;393:1708-20.
17.	Boland BS, He Z, Tsai MS, Olvera JG, Omilusik KD, Duong HG, et al. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. SciImmunol2020;5.
18.	Paludan SR, Pradeu T, Masters SL, Mogensen TH. Constitutive immune mechanisms: Mediators of host defence and immune regulation. Nat Rev Immunol 2021;21:137-50.
19.	Flajnik MF, Kasahara M. Origin and evolution of the adaptive immune system: Genetic events and selective pressures. Nat Rev Gen 2010;11:47-59.
20.	Joosten LA, Abdollahi-Roodsaz S, Dinarello CA, O'neill L, Netea MG. Toll-like receptors and chronic inflammation in rheumatic diseases: New developments. Nat Rev Rheumatol 2016;12:344-57.
21.	Takeda K, Kaisho T, Akira S. Toll-like receptors. AnnRevImmunol 2003;21:335-76.
22.	Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. NatImmunol 2001;2:947-50.
23.	Kordjazy N, Haj-Mirzaian A, Haj-Mirzaian A, Rohani MM, Gelfand EW, Rezaei N, et al. Role of toll-like receptors in inflammatory bowel disease. Pharmacol Res 2018;129:204-15.
24.	Lu Y, Li X, Liu S, Zhang Y, Zhang D. Toll-like receptors and inflammatory bowel disease. FrontImmunol 2018;9:72.
25.	Hug H, Mohajeri MH, La Fata G. Toll-like receptors: Regulators of the immune response in the human gut. Nutrients 2018;10:203.
26.	Levin A, Shibolet O. Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory. World J Gastroenterol 2008;14:5149-53.
27.	Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 2018;49:725-39.e6.
28.	Heger L, Balk S, Lühr JJ, Heidkamp GF, Lehmann CH, Hatscher L, et al. CLEC10A is a specific marker for human CD1c+dendritic cells and enhances their toll-like receptor 7/8-induced cytokine secretion. Front Immunol 2018;9:744.
29.	Takeda K, Akira S. Toll-like receptors in innate immunity. IntImmunol2005;17:1-14.
30.	Coelho T, Mossotto E, Gao Y, Haggarty R, Ashton JJ, Batra A, et al. Immunological profiling of paediatric inflammatory bowel disease using unsupervised machine learning. J Pediatr Gastroenterol Nutr 2020;70:833-40.
31.	Sheehan D, Shanahan F. The gut microbiota in inflammatory bowel disease.Gastroenterol ClinNorth Am2017;46:143-54.
32.	Kozłowska E, Agier J, Wysokiński A, Łucka A, Sobierajska K, Brzezińska-Błaszczyk E. The expression of toll-like receptors in peripheral blood mononuclear cells is altered in schizophrenia.Psychiatry Res 2019;272:540-50.
33.	Takagi M. Toll-like receptor. J Clin Exp Hematopathol2011;51:77-92.
34.	Lavelle EC, Murphy C, O'Neill L, Creagh EM. The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol 2010;3:17-28.
35.	Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007;7:1271-85.
36.	Cario E. Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut 2005;54:1182-93.
37.	Szebeni B, Veres G, Dezsofi A, Rusai K, Vannay A, Mraz M, et al. Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin ExpImmunol 2008;151:34-41.
38.	Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 2010;11:373-84.
39.	Öhman L, Lindmark A-C, Isaksson S, Posserud I, Strid H, Sjövall H, et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. Eur J Gastroenterol Hepatol 2012;24:398-405.
40.	Fan Y, Liu B. Expression of toll-like receptors in the mucosa of patients with ulcerative colitis. Exp Ther Med 2015;9:1455-9.
41.	Tan Y, Zou K-f, Qian W, Chen S, Hou X-h. Expression and implication of toll-like receptors TLR2, TLR4 and TLR9 in colonic mucosa of patients with ulcerative colitis. J Huazhong Univ Sci Technol Med Sci 2014;34:785-90.
42.	Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7.
43.	Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006;212:256-71.
44.	Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011;106:329-36.

Advanced Biomedical Research